DNA Script has announced a distribution agreement with Imperial Life Sciences (ILS) to expand access to the company’s DNA synthesis platform. 

The partnership will mean DNA Script’s SYNTAX platform will now be available in India. Under the agreement, ILS will distribute DNA Script’s SYNTAX platform throughout the country, providing local sales, technical support and application expertise to researchers seeking access to single-stranded DNA (ssDNA) oligonucleotides. 

DNA Script says the SYNTAX platform combines DNA synthesis, purification and normalisation in a single automated workflow, allowing laboratories to produce up to 384 oligonucleotides in parallel and accelerate design-build-test cycles across a wide range of research applications. 

Oligonucleotides are essential components of life sciences research, but many researchers continue to rely on external suppliers, resulting in delays that can slow scientific progress and extend development timelines. DNA Script claims its automated benchtop SYNTAX platform addresses these challenges by enabling researchers to synthesise ssDNA oligonucleotides directly within their laboratories in just a few hours.  

By shifting DNA production from centralised manufacturing facilities to the laboratory bench, researchers could gain greater control over workflows, faster turnaround times and reduced dependence on complex supply chains. 

“India’s life sciences sector is moving fast, and researchers need the tools to match that pace,” said Marc Montserrat, Chief Executive Officer at DNA Script. 

“Partnering with Imperial Life Sciences means laboratories across India can now access SYNTAX locally, with the speed, quality and scalability their research demands.  

“Together, we are helping researchers reduce reliance on external DNA supply chains and accelerate scientific discovery through on-demand, in-house DNA synthesis.”